Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Lobeglitazone and Dapagliflozin in Healthy Volunteers
NCT03616392Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve at steady state over the dosing interval for D308 at Day 5, Maximum plasma concentration at steady state for D308 at Day 5 and 2 more. Started Jul 2018; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03616392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616392.